氨基末端B型钠尿肽在心力衰竭中的临床应用  

The clinical application of the N-terminal pro-B-type natriurefic peptide in heart failure

作　　者：王广洲[1] 周林[1] 

机构地区：[1]苏北人民医院临床医学检测中心,江苏扬州225001

出　　处：《检验医学与临床》2012年第23期2955-2955,2957,共2页Laboratory Medicine and Clinic

摘　　要：目的探讨血浆、尿氨基末端B型钠尿肽(NT-proBNP)在心力衰竭(心衰)患者中的水平变化与心衰分级的关系。方法将88例心衰患者心功能按美国纽约心脏病协会NYHA分级方案分为Ⅰ～Ⅳ级(Ⅰ级25例,Ⅱ级21例,Ⅲ级22例,Ⅳ级20例),同时测定88例患者和43名健康对照者血浆、尿NT-proBNP作比较。结果 NYHA分级Ⅰ～Ⅳ各组患者的血浆、尿NT-proBNP水平均高于健康对照组,差异有统计学意义(P<0.05);随着NYHA分级的升高,血浆、尿NT-proBNP也随之增高,且各组间血浆、尿NT-proBNP浓度差异也有统计学意义(P<0.05)。结论血浆、尿NT-proBNP是诊断充血性心力衰竭(CHF)较好的心肌标志物,能反映CHF病情的严重程度。Objective To investigate the change of the plasma and urine concentrations of N-terminal pro-B-type natriuretic peptide（NT-proBNP） in heart failure（HF） patients and their relationships with HF. Methods 88 HF patients＇ heart functions were classified into level I -IV （ I level 25 cases, II level 21 cases, III level 22 eases and IV level 20 cases）according to the criteria of American New York Heart Association（NYHA）. The plasma and urine concentrations of NT-proBNP were determined and analyzed in the HF group（88 cases）and the control group（43 ca- ses）. Results The levels of plasma and urine NT-proBNP in each subgroup of NYHA class were significantly higher than those in the control group（P^0.05）. With the aggravation of NYHA class,the levels of plasma and urine NT- proBNP were increasing（P〈0.05）. The concentrations of plasma and urine NT-proBNP had significant differences between every 2 subgroups in HF （P〈0.05）. Conclusion The NT-proBNP is a good cardiac marker for the diagnosis of HF. And it also reflects the severity of HF.

关 键 词：氨基末端B型钠尿肽 心力衰竭 临床应用 

分 类 号：R541.61[医药卫生—心血管疾病]